Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Genmab A/S    GMAB   DK0010272202

GENMAB A/S

(GMAB)
  Report
Real-time Estimate Quote. Real-time Estimate CHI-X - 12/01 10:55:00 am
2359 DKK   -1.46%
11:51aGENMAB A/S : Investor Presentation - December 2020
PU
11/25NOVARTIS : Genmab Announces Enapotamab Vedotin Update
AQ
11/24GENMAB A/S : Announces Enapotamab Vedotin Update
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Strengths
  • Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 95% by 2022.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Historically, the company has been releasing figures that are above expectations.
  • Sales forecast by analysts have been recently revised upwards.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • The stock is in a well-established, long-term rising trend above the technical support level at 1705 DKK
Weaknesses
  • Stock prices approach a strong long-term resistance in weekly data at DKK 2462.
  • The stock is currently in contact with a medium-term resistance that must be gotten rid of so as to resume the upward trend.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The firm trades with high earnings multiples: 32.59 times its 2020 earnings per share.
  • The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
Ratings chart
Sector Bio Therapeutic Drugs
1st jan.Capitalisation (M$)Investor Rating
GENMAB A/S61.59%25 135
GILEAD SCIENCES, INC.-6.63%76 052
VERTEX PHARMACEUTICALS4.02%59 224
REGENERON PHARMACEUTICALS37.43%54 464
WUXI APPTEC CO., LTD.57.04%38 135
BIONTECH SE266.71%29 915
BEIGENE, LTD.54.25%23 307
ARGENX SE66.57%13 534
MYOKARDIA, INC.208.58%11 993
-
MIRATI THERAPEUTICS, INC.84.58%11 959
HUALAN BIOLOGICAL ENGINEERI..59.18%11 938
SAREPTA THERAPEUTICS, INC.9.16%11 116
ASCENDIS PHARMA A/S21.28%9 013
NEUROCRINE BIOSCIENCES, INC..-11.10%8 870
ULTRAGENYX PHARMACEUTICAL I..177.55%7 842
DENALI THERAPEUTICS INC.250.00%7 311
More Results
Financials
Sales 2020 9 832 M 1 592 M 1 592 M
Net income 2020 4 689 M 759 M 759 M
Net cash 2020 15 041 M 2 435 M 2 435 M
P/E ratio 2020 32,6x
Yield 2020 -
Capitalization 154 B 24 694 M 24 904 M
EV / Sales 2020 14,1x
EV / Sales 2021 17,1x
Nbr of Employees 712
Free-Float 95,2%
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes